Fosun Pharma USA announced the appointment of Mr. Wenjie Zhang as its new Chief Executive Officer, effective May 9, 2025. Mr. Zhang is a visionary leader with over three decades of business experience in the biopharmaceutical industry.
Fakeeh Care Group and Fosun Pharma Forge Strategic Partnership to Advance Cell & Gene Therapy and Tele-Diagnostics in Saudi Arabia
April 28, 2025, Jeddah –
Fakeeh Care Group has announced a strategic partnership with Fosun Pharma, a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. This partnership is part of Fakeeh Care Group’s ambitious vision to accelerate healthcare innovation in Saudi Arabia and align with the Saudi Vision 2030.
Dr. Mazen Soliman Fakeeh, President of Fakeeh Care Group, emphasized that this collaboration marks a significant step toward enhancing the Kingdom’s healthcare system by introducing cutting-edge therapeutic and diagnostic technologies. “Our goal is to build a sustainable healthcare ecosystem founded on research and innovation, and to ensure access to the world’s most advanced medical solutions,” he stated.
The partnership reflects Fakeeh Care Group’s commitment to working with trusted global players with a proven track record in pioneering and localizing advanced treatments. Fosun Pharma is an international frontrunner in biopharmaceuticals, CAR-T therapies and gene therapy. Its self-developed and approved biologics have benefited more than 750,000 patients worldwide.
In addition, Fosun Pharma has developed advanced platforms in diagnostics, medical devices, and AI-powered digital pathology, accelerating diagnostic processes and enabling effective tele-diagnostic solutions.
Commenting on the strategic alliance,Dr. Sohail Bajammal, CEO of Dr. Soliman Fakeeh Hospital in Jeddah, said: “At Fakeeh Care, we are committed to transferring and localizing advanced medical technologies in Saudi Arabia—including CAR-T treatments for hematological cancers and autoimmune disorders, gene therapies for chronic diseases, and smart tele-diagnostic and monitoring systems.”
Mr. Guo Guangchang, Chairman of Fosun International,expressed his enthusiasm for the partnership: “We look forward to establishing long-term and stable strategic cooperation with Fakeeh Care Group to realize our shared vision of delivering integrated healthcare globally. With Fosun’s global operational capabilities, we intend to achieve sustainable value growth with our Middle Eastern partners and create a new win-win ecosystem.”
The memorandum of understanding outlines that “this future collaboration is more than a technological alliance; it is a shared commitment to reshaping the healthcare landscape in the Kingdom and the region.”
This partnership aspires to become a m odel of excellence in the GCC region for integrating advanced therapeutics and tele-diagnostics, positioning Saudi Arabia as a regional hub for healthcare innovation. Through this alliance, Fakeeh Care Group and Fosun Pharma reaffirm their joint commitment to transforming patient lives through innovation, building long-term strategic partnerships, and supporting the Kingdom’s ambition to become a global center for advanced healthcare aligned with Vision 2030.
We’re excited to join the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, at the San Francisco Marriott Marquis. Let’s Meet! Our team will be at the San Francisco Marriott Marquis, located at 780 Mission St. We look forward to exploring new opportunities and collaborations as we work together to change the future of cancer care.
As we wrap-up #WCLC24 we thank everyone that visited our booth and shared the excitement around our new data release on foritinib (SAF-189s) Vs Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC).
About The REMARK study:
The REMARK study is an Ongoing, Randomized, Open-label, Phase 3 trial that met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in PFS in ALK-TKI naïve NSCLC patients in interim analysis. Median PFS NR vs 13.93 months; HR=0.23, 95%CI：0.14 –0.38, p <0.0001.
Foritinib showed significant improvement of central nervous system (CNS) efficacy vs crizotinib.
CNS-TTP NR vs 19.32 months; HR=0.04, 95%CI：0.01-0.14，p<0.0001.
Foritinib showed improvement in overall survival vs crizotinib. Median OS NR vs 24.94 months; HR=0.60, 95%CI：0.30-1.20.
The safety profile of foritinib was as expected with no new findings.
Stay tuned for new data release at #ESMO24
#WCLC24 #lungcancer #ALK+ #SCLC #GoHenlius #FOSUNPHARMAUSA
Please contact Nadra Belamri nadra.belamri@fosunpharmausa.com for more info about Fosun Pharma USA
(SHANGHAI, China, June 27, 2022) – Fosun Pharma and Amgen today jointly announced a collaboration and license agreement for Fosun Pharma for the commercialization of Amgen’s Otezla® and Parsabiv® in the Chinese Mainland. The collaboration will enable Amgen to bring the two innovative medicines to Chinese patients with psoriasis and chronic kidney disease more quickly by leveraging Fosun Pharma’s commercial capabilities within China.
Wu Yifang, Chairman of Fosun Pharma said: “We are very pleased to enter into this partnership with Amgen to bring two innovative medicines, Otezla® and Parsabiv®, to Chinese patients. With Fosun Pharma’s experience in the areas of autoimmune diseases, including psoriasis, and chronic kidney diseases over the years, we are well aware of Chinese patients’ urgent needs for better treatment options. Going forward, we will work together with Amgen to leverage our presence in these areas to make the medicines accessible to patients, enabling them to benefit from these innovative medicines as soon as possible, control diseases and improve quality of life.”
“This decision – to enter into a collaboration with a local partner – is consistent with our determined focus to bring our innovative medicines to more Chinese patients more quickly,” said Irene Hsu, Vice President & General Manager of Amgen China, ” By out-licensing these two products to a partner with the presence, expertise and credibility of Fosun Pharma in these therapeutic areas, we can give full play to both companies’ advantages to ensure more patients are able to benefit from these innovative medicines, while enabling Amgen to focus on our core general medicines business in cardiovascular disease and bone health in China.”
Otezla® (apremilast tablets) was approved by the National Medical Products Administration of China (NMPA) in August 2021 for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. This approval makes Otezla® the first and currently the only oral phosphodiesterase 4 (PDE4) inhibitor for the treatment of plaque psoriasis in China, providing an additional choice for Chinese patients to manage disease and improve quality of life. China has about 6.5 million patients with psoriasis[1], and 57.3% of them are moderate-to-severe cases[2].
Parsabiv® has been approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) in November 2016 and February 2017 respectively for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Currently Parsabiv® is in the process of market authorization approval (MAA) in China. SHPT is one of the common complications of CKD patients on hemodialysis. The prevalence of adult CKD in China is 10.8%[3]. Data show that by the end of 2019, the number of dialysis patients in China has increased to 735,000[4], among which hemodialysis is the main therapy for dialysis patients in China. The incidence of SHPT in hemodialysis patients is 47%-58%[4].
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, oncolytic viruses, gene therapy and PROTAC, to enhance its innovation capabilities.
Guided by the 4IN strategy (Innovation, Internationalization, Integration, and Intelligentization), Fosun Pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth”, with the mission of creating shareholder values as well as promoting the global networks through strengthening its innovative R&D and in-licensing ability and enriching its product pipelines. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global mainstream medical and health market.
For more information, please visit our official website: www.fosunpharma.com.
Fosun Pharma Forward-looking statements:
This press release contains forward-looking statements. All statements other than statements of historical fact contained in this press release, including, without limitation, the discussions of Fosun Pharma’s business strategies and expectations concerning future operations, margins, profitability, liquidity and capital resources, the future development of Fosun Pharma’s industry and the future development of the general economy of Fosun Pharma’s key markets and any statements preceded by, followed by or that include words and expressions such as “expect”, “seek”, “believe”, “plan”, “intend”, “estimate”, “project”, “anticipate”, “may”, “will”, “would” and “could” or similar words or statements, as they relate to Fosun Pharma’s or its management, are intended to identify forward-looking statements. These statements are subject to certain known and unknown risks, uncertainties and assumptions, which may cause Fosun Pharma’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking information. Subject to the requirements of applicable laws, rules and regulations, Fosun Pharma does not have any and undertakes no obligation to update or otherwise revise the forward- looking statements in this press release, whether as a result of new information, future events or developments or otherwise. In this press release, statements of or references to Fosun Pharma’s intentions are made as of the date of this press release. Any such intentions may change in light of future developments. All forward-looking statements contained in this press release are qualified by reference to the cautionary statements set out above.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit http://www.amgen.com and follow us on http://www.twitter.com/amgen.
About Amgen China
Amgen entered China in 2012 on a mission to serve patients by using science and biotechnology to improve health for Chinese patients and societies. With its headquarters in Shanghai, Amgen China is present in more than 100 cities across the country. In China, Amgen strives to bring innovative therapies to patients in a bid to address the huge unmet needs in in our priority therapeutic areas including cardiovascular disease, bone health, inflammation, and hematology/oncology.
For more information, visit www.amgen.cn and follow us on Amgen China Corporate WeChat account “安进Amgen”.
Reference:
1. 中华医学会皮肤性病学分会银屑病专业委员会.中国银屑病诊疗指南(2018简版)[J].中华皮肤科杂志,2019,52(4):223-230.
2. Chen, K., Wang, G., Jin, H., Xu, J., Zhu, X., Zheng, M., & Gu, H. (2017). Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget, 8(28), 46381–46389.
3. Zhang, L., Wang, F., Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822.
4. 全国血液净化病例信息登记系统, 2020.
SHANGHAI, CHINA and, NEW YORK, USA, January 11, 2022 — Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma”; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group in China and Insilico Medicine (“Insilico”), an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology.
This strategic collaboration includes an AI-driven drug discovery research and development (R&D) collaboration on four biological targets, as well as the co-development of Insilico’s QPCTL program. Insilico will receive a total upfront payment of $13 million for the R&D collaboration projects and the co-development of the QPCTL program, potential milestone-based payments, and share commercialization profits from the QPCTL program. In addition, Fosun Pharma will make an equity investment in Insilico.
“We are pleased to enter into strategic collaboration with Insilico. Fosun Pharma is committed to promoting innovative R&D, and is oriented towards fulfilling unmet clinical needs and improving products’ accessibility. We look forward to working with Insilico to leverage the technological and clinical development strengths of both companies, jointly improving the efficiency of innovative drug R&D, and benefiting more patients worldwide,” said Yifang Wu, Chairman and CEO of Fosun Pharma.
The collaboration aims to combine Insilico’s end-to-end AI-driven drug discovery platforms and Fosun Pharma’s clinical development and commercial expertise to discover and develop a portfolio of novel therapeutics. Pursuant to the collaboration agreement, Insilico will take responsibility for delivering a preclinical candidate for the QPCTL program and advancing it to IND stage, after which, Fosun Pharma will then conduct human clinical studies and co-develop the candidate globally. In parallel, Fosun Pharma’s R&D team will nominate four therapeutic targets to be assessed by Insilico’s AI platform and R&D team, who are responsible of advancing drug candidates to IND stage.
As part of the collaboration, Fosun Pharma will secure access to Insilico’s PandaOmics and Chemistry42 platforms in order to advance Fosun Pharma’s internal AI-powered discovery and development efforts.
“In partnering with Fosun Pharma, a leading pharmaceutical company, we begin a new era of AI-powered end-to-end drug discovery and development as human-machine collaboration becoming the new normal in precision drug discovery and development. We previously demonstrated that AI can be used to discover novel targets and generate novel molecules that can be tested in humans in record time. Now, we are partnering with one of the leading scientific teams in the pharmaceutical industry to take this technology to the next level for the benefit of patients worldwide”, said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine.
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading innovation-driven international healthcare group in China. Fosun Pharma strategically operates businesses in the pharmaceutical and health industry, including pharmaceutical manufacturing, medical devices and medical diagnosis, and healthcare services. Through equity participation in Sinopharm Co., Ltd., Fosun Pharma’s business extends to pharmaceutical distribution and retail.
Fosun Pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. Through in-house R&D, co-development, in-licensing and incubation, Fosun Pharma had established platforms for small molecule innovative drugs, antibody drugs and cell therapy, focusing on major therapeutic areas, including oncology, immunology, “4 hypers” (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system. In the meantime, Fosun Pharma keeps close track of cutting-edge technologies, such as targeted protein degradation, RNA, oncolytic virus and gene therapy to enhance its innovation ability.
Looking forward, under guidance of 4IN strategy (Innovation, Internationalization, Integration and Intelligentization), Fosun Pharma practices innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development. Fosun Pharma is committed to becoming the first-class enterprise in the global mainstream healthcare industry.
For more information, please visit: www.fosunpharma.com.
Fosun Pharma Forward-looking statements
This press release contains forward-looking statements. All statements other than statements of historical fact contained in this press release, including, without limitation, the discussions of the Company’s business strategies and expectations concerning future operations, margins, profitability, liquidity and capital resources, the future development of the Company’s industry and the future development of the general economy of the Company’s key markets and any statements preceded by, followed by or that include words and expressions such as “expect”, “seek”, “believe”, “plan”, “intend”, “estimate”, “project”, “anticipate”, “may”, “will”, “would” and “could” or similar words or statements, as they relate to the Company or its management, are intended to identify forward-looking statements. These statements are subject to certain known and unknown risks, uncertainties and assumptions, which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking information. Subject to the requirements of applicable laws, rules and regulations, the Company does not have any and undertakes no obligation to update or otherwise revise the forward- looking statements in this press release, whether as a result of new information, future events or developments or otherwise. In this press release, statements of or references to the Company’s intentions are made as of the date of this press release. Any such intentions may change in light of future developments. All forward-looking statements contained in this press release are qualified by reference to the cautionary statements set out above.
About Insilico Medicine
Insilico Medicine, an end-to-end AI-driven drug discovery and development company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. Insilico Medicine has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases. For more information, visit www.insilico.com.
For further information, images, or interviews, please contact media@insilicomedicine.com
(15 March 2020, Shanghai, Hong Kong) – Today, Fosun Pharma industrial, a subsidiary company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH, 02196.HK) and BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”) announced a strategic development and commercialization collaboration to advance BioNTech’s mRNA vaccine in China for the prevention of COVID-19 infections.
Under the terms of the agreement, the two Companies will work jointly on the development of COVID-19 vaccines based on BioNTech’s mRNA technology platform in China. The Companies will collaborate to conduct clinical trials in China leveraging Fosun Pharma’s extensive clinical development, regulatory, and commercial capabilities in the country. BioNTech will supply the mRNA vaccine for clinical trials from GMP manufacturing facilities in Europe.
mRNA is a nucleic acid molecule that carries genetic information. The mRNA vaccine introduces the genetic information into the body, so that the cells in the body produce the corresponding antigen, which induces the body to produce neutralizing antibodies and stimulates the response of T cells, and fights against the virus through the dual mechanisms of humoral immunity and cellular immunity. In the face of a sudden epidemic, compared with traditional vaccines, synthesis and production process of mRNA vaccine is more convenient, and has strong immunogenicity, which does not need additional adjuvant as needed by the traditional vaccine, and with good safety.
BioNTech is a leading mRNA technology company that has diversified mRNA platform technologies, integrated R&D system and strong manufacturing capability. “The mRNA technology introduces genetic information into human body, then the body’s own cells produce the corresponding proteins that cure or prevent disease. Fosun Pharma R&D has been tracking the development of this technology. The two companies expect further cooperation in this field,” says Dr. Aimin Hui, President of Fosun Pharma Global R&D.
“We see this collaboration as an important step in our global effort to expedite the development of mRNA vaccines to prevent COVID-19 infection. Fosun Pharma shares our commitment to move rapidly to address the COVID-19 outbreak and brings deep development experience and an extensive network in the pharmaceutical market in China,” says Founder and CEO of BioNTech, Ugur Sahin, M.D.
Wu Yifang, President and CEO of Fosun Pharma states, “A potential pandemic requires a collective effort and both companies are passionate about contributing to the fight against the current coronavirus outbreak. We are excited to collaborate with BioNTech, one of the leading companies worldwide in the mRNA field. Our shared objective is to develop a vaccine against the coronavirus and to be able to rapidly manufacture a vaccine to turn the tide of COVID-19 infection.”
Under the terms of the agreement, Fosun Pharma will pay BioNTech up to $85 million in licensing fees (including a down payment, clinical development registration and sales milestone payments) as agreed, and a sales commission equal to 35% of the product’s annual gross profit during the agreed sales commission period. Meanwhile, Fosun Pharma has agreed to make an equity investment of USD 50 million (EUR 44 million) for 1,580,777 ordinary shares in BioNTech.
